GH secretagogue
CJC-1295 with DAC Dosage, Protocol & Research Guide
Reconstitution calculator
Calculator example, not a recommended amount
- Concentration
- 2.5 mg/mL
- Volume to draw
- 0.1 mL
- Units on a U-100 syringe
- 10 units
Properties
- CAS
- Not yet recorded
- Molecular weight
- Not yet recorded
- Formula
- Not yet recorded
- Sequence
- Not yet recorded
- Aliases
- CJC-1295 DAC
- Vial sizes (mg)
- 5
Storage notes
- Lyophilized
- Not yet recorded from a cited source
- Reconstituted stability (days)
- Not yet recorded from a cited source
Side effects, contraindications and regulatory status
Reported side effects
- Two ascending-dose trials in healthy adults aged 21-61 given CJC-1295 (with DAC) subcutaneously (Teichman 2006): no serious adverse reactions were reported; the authors report it was safe and relatively well tolerated, particularly at 30 or 60 mcg/kg.[2] Human trial
- FDA safety-risk page (nominated-but-withdrawn table, current 2026-04-22): FDA identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction; clinical data are limited. The entry does not say which form (with or without DAC).[1] Regulator or expert-panel statement
Regulatory status
Listed as CJC-1295 (no with/without DAC distinction) in the 'nominated but withdrawn' table of the FDA bulk-substance safety-risk page (current 2026-04-22); no US label. Checked 2026-10-20.[1] Source
Report any adverse reaction to a qualified healthcare professional.
What the research says
Summaries of the cited studies, each with its evidence grade.
pubmed.ncbi.nlm.nih.gov[2]
Two randomized double-blind placebo-controlled ascending-dose trials in healthy adults aged 21-61 (J Clin Endocrinol Metab 2006, doi 10.1210/jc.2005-1536): CJC-1295 (long-acting DAC form) subcutaneously in one of four ascending single doses (28-day study) and in two or three weekly or biweekly doses (49-day study); abstract reports estimated half-life 5.8-8.1 days and names 30 and 60 microg/kg
Single-injection GH pulsatility study in healthy men aged 20-40 (J Clin Endocrinol Metab 2006, doi 10.1210/jc.2006-1702)[3]
Single-injection GH pulsatility study in healthy men aged 20-40 (J Clin Endocrinol Metab 2006, doi 10.1210/jc.2006-1702): CJC-1295 (long-acting DAC form, half-life 8 d per the abstract) at 60 or 90 microg/kg, 12-hour overnight GH sampling every 20 minutes before and 1 week after injection
Compare vial sizes
| Size | Price | Doses available from the vial Calculated | Cost per dose Calculated |
|---|---|---|---|
| 5 mg | $69.99 | — | — |
Cost per dose uses the listed partner price and the reference dose cited on this page. Prices change; check the product page.
Calculated from a default of 2 mL water (adjustable).
Peptide Protocol Check may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.
Frequently asked questions
What study duration is cited for CJC-1295 with DAC?
The cited duration is 7 weeks, with no off period stated (Human clinical trial). It describes the source, not a recommendation.
What is the regulatory status of CJC-1295 with DAC?
Listed as CJC-1295 (no with/without DAC distinction) in the 'nominated but withdrawn' table of the FDA bulk-substance safety-risk page (current 2026-04-22); no US label. Checked 2026-10-20.
Compound facts
What is the molecular weight of CJC-1295 with DAC?
What is the CAS number of CJC-1295 with DAC?
How is CJC-1295 with DAC stored in the laboratory?
References
Numbered sources used on this page. Markers in the text link here.
- fda.gov Regulator or expert-panel statement
- pubmed.ncbi.nlm.nih.gov Human trial
- Single-injection GH pulsatility study in healthy men aged 20-40 (J Clin Endocrinol Metab 2006, doi 10.1210/jc.2006-1702) pubmed.ncbi.nlm.nih.gov Human trial
Vial sizes and protocols
5 mgPartner size
Available from Pepcore
Supplied as research material for laboratory use only.
- Shop at PepcoreCoupon code
LAUNCH20
Peptide Protocol Check may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.